Document:

Exhibit 10.3 

 

SEPARATION
AND Release Agreement

 

THIS SEPARATION AND RELEASE
AGREEMENT (this “Agreement”) is made and entered into as of November 3, 2021 by and between NeuroBo
Pharmaceuticals, Inc., a Delaware corporation, whose address is 200 Berkeley Street, Office 19th Floor, Boston,
Massachusetts 02116 (the “Company”) and Richard Kang, Ph.D. whose
address is as reflected in the personnel records of the Company (“Employee”). Capitalized terms used but not
defined in this Agreement will have the meanings ascribed to them in that Employment Agreement between Employee and the Company dated
February 11, 2020 (the “Employment Agreement”).

 

Recitals

 

Whereas,
Employee has been employed as the Chief Executive Officer and President of the Company since January 1, 2020; and

 

Whereas,
the Company and Employee (collectively, the “Parties” and each, without distinction, a “Party”)
have mutually agreed to terminate Employee’s existing employment relationship with the Company on the terms and conditions set forth
in this Agreement.

 

Agreement

 

Now,
therefore, in consideration of the foregoing premises and for other good and valuable consideration, the receipt and sufficiency
of which are hereby expressly acknowledged, the Parties, intending to be legally bound, hereby agree as follows:

 

Article 1

EMPLOYMENT TERMINATION, PAYMENTS AND RESIGNATION

 

1.1            Termination
of Employment. Employee’s employment with the Company shall terminate on the earliest to occur of: (i) the
day immediately following the filing by the Company with the United States Securities and Exchange Commission (the “SEC”)
of a Quarterly Report on Form 10-Q the period ended September 30, 2021 or (ii) such earlier date as determined by Chairman
of the Board of Directors of the Company (the “Resignation Date”). From the date of this Agreement through the
Resignation Date, Employee will perform such transition and other duties as assigned by the Company. Effective as of the Resignation Date,
Employee hereby resigns from every office of the Company and the Company’s subsidiaries held by Employee; provided, however, Employee
shall continue to serve on the Company’s Board of Directors for the remainder of Employee’s current term until the earlier
of the annual meeting of the Company’s stockholders to be held in 2022, the election and qualification of Employee’s successor,
or until Employee’s resignation or removal from the Company’s Board of Directors. Additionally, following the Resignation
Date, Employee shall continue to serve as an officer and on the governing body of the Company’s subsidiary, NeuroBo Co., Ltd.,
until the election and qualification of Employee’s successor, or until Employee’s resignation or removal from such position
at NeuroBo Co., Ltd. The Company shall pay Employee’s compensation for hours worked through the Resignation Date, subject to
withholding and payable in accordance with the Company’s payroll practices. The Company will also pay Employee for Employee’s
accrued but unused Paid Time Off with Employee’s final paycheck, subject to withholding and payable in accordance with the Company’s
payroll practices. In addition, the Company will reimburse Employee for Employee’s outstanding documented business expenses remaining
on the Company’s books, which were properly reviewed and approved according to the Company’s policies in effect on the Resignation
Date. Employee will receive the above payments regardless of whether Employee signs this Agreement and regardless of whether this Agreement
becomes effective in accordance with Section 2.2. All of Employee’s benefits through the Company will end on the Resignation
Date.

 

1.2            Resignation
Consideration. As consideration for Employee’s agreements and releases set forth herein, and provided that Employee
executes and delivers this Agreement (without revoking same), executes and delivers the Signature to Update Release Provision appearing
after the signature page (without revoking the same) on or within seven (7) days after the Resignation Date, and Employee remains
in compliance with Employee’s obligations under this Agreement, then:

 

(a)            The
Company will pay Employee the aggregate sum of $150,000.00, which shall be paid in accordance with the Company’s normal payroll
practices in substantially equal amounts over our (4) months commencing within 60 days after the Resignation Date, subject to payroll
deductions and all required withholdings;

 

    	 	1	 

     

    

 

(b)            An
amount equal to $130,680.00, as the prorated amount of Employee’s annual bonus for 2021, payable by the Company within sixty (60)
days of the Resignation Date;

 

(c)            The
Company agrees to engage Employee to provide consulting services, and Employee agrees to provide consulting services, pursuant to the
terms and conditions of the consulting agreement attached hereto as Exhibit A
(the “Consulting Agreement”); and

 

(d)            Beginning
on the first day of the month following the Resignation Date and continuing through the date that is the twelve (12) month anniversary
of the Resignation Date (the “COBRA Period”), subject to Employee’s valid election to continue healthcare
coverage under Section 4980B of the Internal Revenue Code of 1986, as amended and the regulations thereunder (the “Code”),
the Company shall continue to provide Employee and Employee’s eligible dependents with coverage under the Company’s group
health plans at the same levels and the same cost to Employee as would have applied if Employee’s employment had not been terminated
based on Employee’s elections in effect on the Resignation Date (subject to any increase or decrease in such costs to Employee during
the COBRA Period that apply to others on such plan), provided, however, that (x) if any plan pursuant to which such benefits are
provided is not, or ceases prior to the expiration of the period of continuation coverage to be, exempt from the application of Section 409A
(as defined below) under Treasury Regulation Section 1.409A-1(a)(5), or (y) the Company is otherwise unable to continue to cover
Employee under its group health plans without incurring penalties (including without limitation, pursuant to Section 2716 of the
Public Health Service Act), then, in either case, an amount equal to each remaining Company subsidy shall thereafter be paid to Employee
in substantially equal monthly installments over the continuation coverage period (or the remaining portion thereof).

 

1.3            Conflict
with Other Agreements. In the event of any conflict of the provisions between this Agreement and the Employment Agreement,
the provisions set forth in this Agreement shall control. Notwithstanding the foregoing, Employee agrees to strictly comply with Employee’s
remaining obligations under the Employment Agreement which survive the Resignation Date, including, but not limited to, Section 6,
Section 7 and Sections 9 through 22 of the Employment Agreement. In the event of any conflict of the provisions between this Agreement
and the provisions of that certain Indemnification Agreement dated effective as of December 31, 2019 entered into by and between
the Company and Employee (the “Indemnification Agreement”), the provisions set forth in the Indemnification
Agreement shall control.

 

1.4            Acknowledgement.
Except as provided in this Article 1, the Parties acknowledge and agree that Employee is not, and shall not after the Resignation
Date, be eligible for any additional payment by the Company of any bonus, salary, vacation pay, retirement pension, severance pay, back
pay, or other remuneration or compensation of any kind in respect of employment by the Company or its affiliates. Employee further agrees
that Section 6, Section 7 and Sections 9 through 22 of the Employment Agreement remains in full force and effect, and Employee
hereby reaffirms Employee’s obligations arising under Section 6, Section 7 and Sections 9 through 22 of the Employment
Agreement. Employee agrees to return to the Company all of the Company’s documents and materials, apparatus, equipment and other
physical property in Employee’s possession within five (5) days of the Resignation Date and in the manner directed by the Chairman
of the Board of Directors of the Company (the “Chairman”).

 

1.5            Cooperation
and Assistance. Following the Resignation Date, Employee agrees to furnish such information and assistance to the Company
as may be reasonably required by the Company in connection with any issues or matters of which Employee had knowledge during Employee’s
employment with the Company. In addition, following the Resignation Date, Employee agrees to be reasonably available to assist the Company
in matters relating to the transition of Employee’s prior duties to other employees of the Company, as may be reasonably requested
by the Company. Following the Resignation Date, the Company shall reimburse Employee for the reasonable documented out-of-pocket expenses
incurred by Employee in providing such cooperation and assistance; provided that any such expense exceeding Five Hundred Dollars ($500)
shall require the advance written consent of the Chairman. Any services rendered by Employee following the Resignation Date pursuant to
this Section 1.5 shall be governed by the applicable terms and conditions of the Consulting Agreement. Following the Resignation
Date, Employee shall promptly deliver to the Chairman all correspondence and any inquires that Employee receives (including the contents
of any telephone calls or emails received by Employee) from any third party concerning any issue of significance to the Company.

 

    	 	2	 

     

    

 

1.6            Statement
Regarding Resignation; SEC Matters.  Employee acknowledges that the Company may be required to file a copy of this Agreement
as an exhibit to a Form 8-K or Form 10-Q filed with the SEC (the “Exchange Act Reports”). Employee
agrees that the Exchange Act Reports may contain a statement summarizing the terms and conditions of this Agreement and the fact that
Employee’s employment with the Company terminated as of the Resignation Date (the “Exchange Act Statement”).
Employee will cooperate with the Company in providing information with respect to all reports required to be filed by the Company with
the SEC as they relate to required information with respect to Employee. Further, following the Resignation Date, Employee will remain
in compliance with the terms of the Company’s insider trading policy with respect to purchases and sales of the Company’s
securities.

 

1.7            Standstill.
Employee agrees that, for a period of two (2) years from the Resignation Date, neither Employee nor any of Employee’s affiliates
or representatives acting on Employee’s behalf or on behalf of other persons acting in concert with Employee will in any manner,
directly or indirectly: (a) effect or seek, offer or propose (whether publicly or otherwise) to effect, or announce any intention
to effect or cause or participate in or in any way assist, facilitate or encourage any other person to effect or seek, offer or propose
(whether publicly or otherwise) to effect or participate in, (i) any acquisition of any securities (or beneficial ownership thereof),
or rights or options to acquire any securities (or beneficial ownership thereof), or any assets, indebtedness or businesses of the Company
or any of its subsidiaries or affiliates, (ii) any tender or exchange offer, merger or other business combination involving the Company,
any of the subsidiaries or affiliates or assets of the Company or the subsidiaries or affiliates constituting a significant portion of
the consolidated assets of the Company and its subsidiaries or affiliates, (iii) any recapitalization, restructuring, liquidation,
dissolution or other extraordinary transaction with respect to the Company or any of its subsidiaries or affiliates, or (iv) any
 “solicitation” of “proxies” (as such terms are used in the proxy rules of the SEC) or consents to vote any
voting securities of the Company or any of its affiliates; (b) form, join or in any way participate in a “group” (as
defined under Securities Exchange Act of 1934, as amended) with respect to the Company or otherwise act in concert with any person in
respect of any securities of the Company; (c) otherwise act, alone or in concert with others, to seek representation on or to control
or influence the management, the Company’s Board of Directors or policies of the Company or to obtain representation on the Company’s
Board of Directors; (d) take any action which would or would reasonably be expected to force the Company to make a public announcement
regarding any of the types of matters set forth in (a) above; or (e) enter into any discussions or arrangements with any third
party with respect to any of the foregoing. Employee also agrees during such period not to request (in any manner that would reasonably
be likely to cause the Company to disclose publicly) that the Company or any of its representatives, directly or indirectly, amend or
waive any provision of this Section 1.7 (including this sentence).

 

Article 2

RELEASES AND NON-DISPARAGEMENT

 

2.1            Employee
Release of Claims. In consideration for the separation consideration set forth in this Agreement, Employee, on behalf
of Employee, Employee’s heirs, executors, legal representatives, spouse and assigns (the “Employee Releasing Parties”),
hereby fully and forever releases the Company and the Company’s past and present officers, directors, employees, investors, stockholders,
administrators, subsidiaries, affiliates, predecessor and successor corporations, assigns, attorneys and insurers (each a “Company
Released Party”, and collectively, the “Company’s Released Parties”) of and from any claim,
duty, obligation or cause of action relating to any matters of any kind, whether presently known or unknown, suspected or unsuspected,
that any of them may possess arising from any omissions, acts or facts that have occurred through the date that Employee signs this Agreement,
including, without limitation, any and all claims:

 

(a)            which
arise out of, result from, or occurred in connection with Employee’s employment by the Company or any of its affiliated entities,
the termination of that employment relationship, any events occurring in the course of that employment, the Employment Agreement, or any
events occurring prior to the execution of this Agreement;

 

    	 	3	 

     

    

 

(b)            for
discrimination, harassment and/or retaliation; breach of contract, both express and implied; breach of a covenant of good faith and fair
dealing, both express and implied; negligent or intentional infliction of emotional distress; negligent or intentional misrepresentation;
negligent or intentional interference with contract or prospective economic advantage; slander, libel or invasion of privacy; violation
of public policy; fraud, misrepresentation or conspiracy; and false imprisonment;

 

(c)            (i) wrongful
discharge of employment, any and all claims for wrongful discharge of employment, and/or (ii) violation of any federal, state or
municipal statute relating to employment or employment discrimination, including, without limitation, (A) Title VII of the Civil
Rights Act of 1964, as amended, (B) the Civil Rights Act of 1866, as amended, (C) the Civil Rights Act of 1991, as amended,
(D) the Employee Retirement and Income Security Act of 1974, as amended, (E) the Age Discrimination in Employment Act of 1967,
as amended (the “ADEA”), including, without limitation, by the Older Workers’ Benefit Protection Act,
as amended (“OWBPA”), (F) the OWBPA, (G) the Americans with Disabilities Act of 1990, as amended,
(H) any applicable state Persons with Disabilities Civil Rights Act, as amended, (I) any applicable state Whistleblowers Protection
Act, as amended, (J) Genetic Information Nondiscrimination Act (GINA), and (K) the Immigration Reform and Control Act (IRCA);

 

(d)            under
Massachusetts common law or state statute including, but not limited to, those alleging wrongful discharge, express of implied breach
of contract, negligence, invasion of privacy, intentional infliction of emotional distress, fraud, defamation, or any claims arising out
of the Massachusetts Fair Employment Practices Act, Mass. Gen. Laws ch. 151B, § 1 et seq., Mass. Gen. Laws ch. 149, § 148 et
seq. (Massachusetts law regarding payment of wages and overtime), the Massachusetts Civil Rights Act, Mass. Gen. Laws ch. 12, §§
11H and 11I, the Massachusetts Equal Rights Act, Mass. Gen. Laws. ch. 93, § 102 and Mass. Gen. Laws ch. 214, § 1C, the Massachusetts
Labor and Industries Act, Mass. Gen. Laws ch. 149, § 1 et seq., Mass. Gen. Laws ch. 214, § 1B (Massachusetts right of privacy
law), the Massachusetts Maternity Leave Act, Mass. Gen. Laws ch. 149, § 105D, and the Massachusetts Small Necessities Leave Act,
Mass. Gen. Laws ch. 149, § 52D, all as amended, all as amended together with all of their respective implementing regulations, and/or
any other federal, state, local or foreign law (statutory, regulatory or otherwise) that may be legally waived and released;

 

(e)           for
back pay or other unpaid compensation;

 

(f)            relating
to equity of the Company; and/or

 

(g)           for
attorneys’ fees and costs.

 

To
the fullest extent permitted by law, Employee will not take any action that is contrary to the covenants and agreements Employee has made
in this Agreement. Employee represents that Employee has not filed any lawsuit, arbitration, or other claim against any of the
Company’s Released Parties. Employee states that Employee knows of no violation of state, federal, or municipal law or regulation
by any of the Company’s Released Parties, and knows of no ongoing or pending investigation, charge, or complaint by any agency charged
with enforcement of state, federal, or municipal law or regulation. While nothing in this Agreement prevents state or federal agencies
from enforcing laws within their jurisdictions, Employee agrees Employee shall not receive any individual monetary damages, recovery and/or
relief of any type related to any released claim(s), whether pursued by Employee or any governmental agency, other person or group; provided
that nothing in the Agreement prevents Employee from participating in the whistleblower program maintained by the SEC and receiving a
whistleblower award thereunder. Employee hereby agrees that the release set forth in this Agreement shall be and remain in effect in all
respects as a complete general release as to the matters released. Notwithstanding anything in this Agreement to the contrary, nothing
herein release any claim for indemnification, contribution, defense or coverage, from or through the Company or its insurers, under the
Company’s (or its affiliates’) charter, By-laws, the Indemnification Agreement, applicable law, or applicable insurance policies,
with respect to prior actions or inactions relating in any way to Employee’s duties as an employee or officer of the Company. Each
Company Released Party is an intended third party beneficiary of this Agreement and entitled to enforce the release in this Section 2.1
as if such Company Released Party was a Party to this Agreement.

 

    	 	4	 

     

    

 

2.2            Acknowledgment
of Waiver of Claims under ADEA. Employee acknowledges that Employee is waiving and releasing any rights Employee may
have under the OWBPA, the ADEA, and otherwise, and that this waiver and release is knowing and voluntary. Employee acknowledges that the
consideration given for this waiver and release is in addition to anything of value to which Employee was already entitled. Employee further
acknowledges that Employee has been advised by this writing that (a) Employee should consult with an attorney prior to executing
this Agreement; (b) Employee has twenty-one (21) calendar days within which to consider this Agreement and that, if Employee executed
this Agreement before expiration of that twenty-one (21) calendar day period, Employee did so knowingly and voluntarily and with the intent
of waiving Employee’s right to utilize the full twenty-one (21) calendar day consideration period; (c) Employee has seven (7) days
following Employee’s execution of this Agreement to revoke this Agreement (the “Revocation Period”). Communication
of any such revocation by Employee to the Company shall be provided in writing and mailed by certified or registered mail with return
receipt requested and shall be addressed to the Company at its principal corporate offices to the attention of the Chairman. This Agreement
shall not be effective until the Revocation Period has expired without any revocation having been communicated.

 

2.3            No
Admission of Liability. Neither this Agreement nor any statement contained herein shall be deemed to constitute an admission
of liability on the part of the parties herein released. This Agreement’s execution and implementation may not be used as evidence,
and shall not be admissible in a subsequent proceeding of any kind, except one alleging a breach of this Agreement, the Indemnification
Agreement or the Employment Agreement.

 

2.4            Non-Disparagement.
To the fullest extent permitted by law, Employee covenants and agrees that Employee shall not make or cause to be made
any statements, observations, opinions or communicate any information (whether in written or oral form) that defames, slanders or is likely
in any way to harm the reputation of the Company or any of its subsidiaries, affiliates, directors, or officers or tortiously interfere
with any of the other Company’s business relationships. Any violation of the covenant contained in this Section 2.4
will result in irreparable damage and the Company shall be entitled to injunctive and other equitable relief.

 

Article 3

REPRESENTATIONS AND WARRANTIES

 

3.1            Representations
and Warranties of Employee. Employee warrants and represents to the Company that Employee:

 

(a)            has
been advised to consult with legal counsel in entering into this Agreement;

 

(b)            has
entirely read this Agreement;

 

(c)            has
voluntarily executed this Agreement without any duress or undue influence and with the full intent of releasing all claims;

 

(d)            has
received no promise, inducement or agreement not herein expressed with respect to this Agreement or the terms of this Agreement;

 

(e)            is
the only person (other than Employee’s heirs) who is or may be entitled to receive or share in any damages or compensation on account
of or arising out of Employee’s relationship with, or providing services to, the Company or any of its affiliated entities, the
termination of that relationship or services, any actions taken in the course of that relationship or services, and any events related
to that relationship or services or occurring prior to the execution of this Agreement;

 

(f)             understands
and agrees that in the event any injury, loss, or damage has been sustained by Employee which is not now known or suspected, or in the
event that the losses or damage now known or suspected have present consequences not known or suspected, this Agreement shall nevertheless
constitute a full and final release as to the parties herein released, and that this Agreement shall apply to all such unknown or unsuspected
injuries, losses, damages or consequences; and

 

(g)            expressly
acknowledges that Employee’s entry into this Agreement is in exchange for consideration in addition to anything of value to which
Employee is already entitled.

 

3.2            Authority.
Employee represents and warrants that Employee has the capacity to act on Employee’s own behalf and on behalf of all who might claim
through Employee to bind them to the terms and conditions of this Agreement. Employee represents and warrants that Employee has not assigned
any claim released under this Agreement, and there are no liens or claims of lien or assignments in law or equity or otherwise of or against
any of the claims or causes of action released herein.

 

    	 	5	 

     

    

 

3.3            No
Other Representations. Neither Party has relied upon any representations or statements made by the other Party hereto
which are not specifically set forth in this Agreement.

 

Article 4

MISCELLANEOUS

 

4.1            Severability.
Should any provision of this Agreement be declared or be determined by any arbitrator or court of competent jurisdiction to be illegal
or invalid, the validity of the remaining parts, terms or provisions shall not be affected thereby and said illegal or invalid part, term,
or provision shall be deemed not to be a part of this Agreement.

 

4.2            Entire
Agreement. This Agreement together with the Indemnification Agreement and the Consulting Agreement represents the entire
agreement and understanding between the Company and Employee concerning Employee’s separation from the Company, and supersedes and
replaces any and all prior agreements and understandings concerning Employee’s relationship with the Company and Employee’s
compensation by the Company, including without limitation the Employment Agreement, provided, however, that this Agreement does not supersede
or modify any continuing obligations of Employee under the Employment Agreement that do not conflict with the terms and conditions of
this Agreement, all of which shall continue in full force and effect except as modified here. This Agreement may only be amended by a
writing signed by Employee and the Company.

 

4.3            Assignment.
This Agreement may not be assigned by Employee without the prior written consent of the Company. The Company may assign this Agreement
without Employee’s consent in connection with a merger or sale of its assets and/or to a corporation controlling, controlled by
or under common control with the Company. This Agreement shall inure to the benefit of, and be binding upon, each Party’s respective
heirs, legal representatives, successors and assigns.

 

4.4            Section 409A.
The provisions of this Agreement shall be interpreted and applied in such a manner that all payments required to be made hereunder either
comply with Section 409A of the Code and the Department of Treasury regulations and other interpretive guidance issued thereunder
(including, without limitation, such guidance as may be issued after the Resignation Date) (“Section 409A”)
or are exempt from the requirements of Section 409A. Any reimbursement of expenses to which Employee is entitled under this Agreement
shall, if subject to Section 409A, be made within the time period and be subject to the other terms and conditions prescribed in
the Employment Agreement. To the extent that any amounts payable hereunder are determined to constitute “nonqualified deferred compensation”
within the meaning of Section 409A, such amounts shall be subject to such additional rules and requirements as specified by
the Company from time to time in order to comply with Section 409A. Each separately identified payment hereunder is to be treated
as a “separate payment” for purposes of Section 409A. Notwithstanding the foregoing, neither the Company nor any other
person guarantees that any particular federal or state income, payroll, personal property or other tax consequence will result under this
Agreement, and neither the Company nor any other person shall be liable for any federal or state tax consequence resulting from this Agreement.

 

4.5            Governing
Law; Consent to Jurisdiction, Waiver of Jury Trial. This Agreement shall be governed by and construed in accordance with the
internal laws of the Commonwealth of Massachusetts, without regard to its principles of conflicts of laws. Each of the Parties hereto
irrevocably submits to the exclusive jurisdiction of the state and federal courts of the Commonwealth of Massachusetts for the purpose
of any suit, action, proceeding or judgment relating to or arising out of this Agreement and the transactions contemplated hereby. Service
of process in connection with any such suit, action or proceeding may be served on each Party hereto anywhere in the world by the same
methods as are specified for the giving of notices under this Agreement.  Each of the Parties hereto irrevocably consents to the
jurisdiction of any such court in any such suit, action or proceeding and to the laying of venue in such court.  Each Party hereto
irrevocably waives any objection to the laying of venue of any such suit, action or proceeding brought in such courts and irrevocably
waives any claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum.  EACH
OF THE PARTIES HERETO WAIVES ANY RIGHT TO REQUEST A TRIAL BY JURY IN ANY LITIGATION WITH RESPECT TO THIS AGREEMENT AND REPRESENTS THAT
COUNSEL HAS BEEN CONSULTED SPECIFICALLY AS TO THIS WAIVER. In addition, should it become necessary for the Company to seek to enforce
any of the covenants contained in this Agreement through any legal, administrative or alternative dispute resolution proceeding, Employee
shall reimburse the Company for its reasonable fees and expenses (legal costs, attorneys’ fees and otherwise) related thereto.

 

    	 	6	 

     

    

 

4.6            Counterparts/Electronic
Execution and Delivery. This Agreement may be executed in one or more counterparts and by facsimile or by electronic
delivery, each of which shall constitute an original and all of which together shall constitute one and the same instrument. Signatures
of the Parties transmitted by facsimile or via .pdf format shall be deemed to be their original signatures for all purposes. The words
 “execution,” “signed,” “signature,” and words of like import shall be deemed to include electronic
signatures or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as
a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for
in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the Massachusetts Uniform Electronic
Transactions Act, or any other similar state laws based on the Uniform Electronic Transactions Act. This Agreement and any signed agreement
or instrument entered into in connection with this Agreement, and any amendments hereto or thereto, to the extent delivered by means of
a facsimile machine or electronic mail (any such delivery, an “Electronic Delivery”), will be treated in all
manner and respects as an original agreement or instrument and will be considered to have the same binding legal effect as if it were
the original signed version thereof delivered in person. At the request of any Party hereto or to any such agreement or instrument, each
other Party hereto or thereto will re-execute original forms thereof and deliver them to all other Parties. No Party hereto or to any
such agreement or instrument will raise the use of Electronic Delivery to deliver a signature or the fact that any signature or agreement
or instrument was transmitted or communicated through the use of Electronic Delivery as a defense to the formation of a contract, and
each such Party forever waives any such defense, except to the extent such defense related to lack of authenticity.

 

Signatures
on the Following Page

 

    	 	7	 

     

    

 

In
Witness Whereof, the Parties have executed and delivered this Agreement as of the date first written above.

 

	The Company:	 	EMPLOYEE:
	 	 	 
	NeuroBo Pharmaceuticals, Inc.  	 	 
	 	 	 
	 	 	 
	By:	/s/ Douglas J. Swirsky	 	/s/
Richard Kang
	Name:	Douglas J. Swirsky	 	Richard Kang, Ph.D.
	Title:	Chairman of the Board	 	Date: November 3, 2021

 

Signature
Page to

Separation
and Release Agreement

 

     

     

    

 

Signature
to Update Release Provision:

(To be signed by Employee on or within seven
(7) days after the Resgination Date)

 

Capitalized terms used below have the meanings
set forth in the foregoing Separation and Release Agreement (the “Agreement”). In consideration of the promises
set forth in the Agreement, Employee, on behalf of himself and the Employee Releasing Parties, fully and forever releases, acquits, and
discharges the Company’s Released Parties from any liability relating to any claims and rights that may have arisen between Employee
signature date on the preceding signature page and Employee’s signature date referenced below, consistent with Employee’s
initial release of claims set forth under Section 2.1 of the Agreement.

 

	By:	 	 	Date:	 	, 2021
	Richard Kang, Ph.D.   	 	 

 

Signature
Page to

Updated
Release Effective On Resignation Date

 

     

     

    

 

Exhibit A

 

CONSULTING
AGREEMENT

 

This Consulting
Agreement (this “Agreement”) is made and entered into this ___ day of November, 2021 (the “Effective
Date”) by and between NeuroBo Pharmaceuticals, Inc., a Delaware
corporation, with its principal place of business at 200 Berkeley Street, 19th Floor, Boston, Massachusetts, 02116 (the “Company”),
and Richard Kang, Ph.D., whose address is as reflected in the personnel records of
the Company (“Consultant”).

 

Recitals

 

The Company desires to retain
Consultant, and Consultant desires to be engaged by the Company, to perform certain consulting services pursuant to the terms and conditions
of this Agreement.

 

Agreement

 

Now,
Therefore, in consideration of the terms, conditions and covenants hereinafter set forth, the Company and Consultant hereby
agree as follows:

 

1.            Duties
of Consultant. In consideration of compensation provided for in Section 2, Consultant hereby agrees to perform
the consulting services during the Consultation Period (as defined below) to be performed by Consultant on behalf of the Company as described
on Exhibit A attached hereto (collectively, the “Services”).
Consultant will become familiar with and comply with the Company’s policies and as requested by the Company from time to time, Consultant
will execute a statement of acknowledgement and agreement that Consultant has read and will comply with the Company’s compliance
policies. Consultant represents, acknowledges and agrees: (a) all of the Services to be performed by Consultant under the terms and
conditions of this Agreement will be performed in full compliance with all applicable laws, rules and regulations; and (b) Consultant
will duly and timely make all filings required under all laws, rules and regulations with respect to the performance of the Services
during the Consultation Period.

 

2.            Consideration.

 

(a)            Compensation.
In consideration of Consultant’s performance of the Services, the Company shall pay Consultant $10,000.00 per month on the last
day of each month for the Services rendered by Consultant during the Consultation Period (as defined below).

 

(b)            Taxes
and IRS Form 1099. The Company will, if applicable, issue an IRS Form 1099 to Consultant for all compensation paid
by the Company to Consultant under this Agreement. Consultant will file all income, unemployment, and/or other employment tax returns,
and pay all income, unemployment, and/or other employment taxes, applicable to the compensation received by Consultant hereunder, in a
manner consistent with Consultant being an independent contractor, and not an employee, of the Company. Upon the Company’s request,
Consultant shall provide documentation demonstrating that Consultant has paid all required taxes with respect to the compensation provided
pursuant to this Agreement.

 

3.            Expenses.
The Company shall reimburse Consultant for reasonable, documented and actual expenses incurred by Consultant in connection with Consultant’s
performance of the Services; provided, however, that Consultant shall not incur any such expense relating to a single activity or trip
in excess of $500 (the “Threshold Amount”) without first obtaining the written consent and approval of the Company.
The Company shall make any such reimbursement within thirty (30) days after receipt of an invoice therefor, accompanied by receipts, vouchers
or other written evidence of the expenses incurred. The Company shall have no obligation to reimburse Consultant for expenses in excess
of the Threshold Amount that were not approved in advance by the Company.

 

4.            Term;
Termination.

 

(a)            Subject
to the terms and conditions set forth in Section 4(b), the term of Consultant’s engagement (hereinafter referred to
as the “Consultation Period”) shall commence on the Effective Date and shall continue until the twelve (12)
month anniversary of the Effective Date, unless extended by mutual written agreement of Consultant and the Company for additional periods.

 

    Exhibit A - 1

     

    

 

(b)            Notwithstanding
the foregoing, either party may terminate this Agreement immediately upon occurrence of any of the following events: (a) the material
breach of this Agreement by the other party, which breach is not cured within ten (10) days after written notice of such breach;
(b) embezzlement, fraud or deceit in the performance of the other party’s obligations hereunder; or (c) Consultant’s
breach of that certain Separation and Release Agreement between the Company and Consultant (the “Separation Agreement”).
In the event of any such termination, Consultant shall be entitled to payment for the Services performed and expenses paid or incurred
prior to the effective date of termination, subject to the limitation on reimbursement of expenses set forth in Section 3.
Such payments shall constitute full settlement of any and all claims of Consultant of every description against the Company. The following
provisions shall survive termination or expiration of this Agreement: Sections 5, 6 and 8 through 21.

 

5.            Confidentiality.
For the Consultation Period and five (5) years thereafter, Consultant shall maintain in confidence and shall not disclose to any
person or entity other than officers, directors and employees of the Company any information obtained by Consultant in the course of Consultant’s
duties under this Agreement in connection with the Company’s products, processes, know-how, formulas, business plans, forecasts,
financial information, customer lists and any other information divulged by the Company to Consultant and identified by the Company to
Consultant as proprietary or confidential (collectively, the “Confidential Information”). Upon the termination
or expiration of this Agreement, Consultant shall promptly destroy or return the Confidential Information in written or digital form to
the Company. All documents, data, records, apparatus, equipment and other physical property, whether or not pertaining to the Confidential
Information, furnished to Consultant by the Company or produced by Consultant or others in connection with Consultant’s engagement
hereunder, shall be owned by the Company and promptly returned to the Company as and when requested. Confidential Information shall not
include any information which: (a) was already known to Consultant at the time of its disclosure to Consultant by the Company; (b) at
the time of disclosure to Consultant was generally available to the public; (c) subsequent to such disclosure becomes generally available
to the public without fault on Consultant’s part; or (d) otherwise becomes known to Consultant on a non-confidential basis
from another source not bound by a confidentiality agreement with the Company. Consultant is aware of the restrictions imposed by the
United States securities laws on the purchase or sale of securities by any person who has received material, nonpublic information from
the issuer of the securities or any affiliate thereof and on the communication of such information to any other person when it is reasonably
foreseeable that such other person is likely to purchase or sell such securities in reliance on such information for so long as the information
remains material and non-public. Consultant is also aware that the Company is requiring Consultant to agree to the restrictions set forth
in this Section 5 to, among other things, fulfill the Company’s obligations under Regulation FD under the Securities
Exchange Act of 1934, as amended.

 

6.            Inventions.
Consultant will promptly and fully disclose to the Chairman of the Board of Directors of the Company any invention, improvement, discovery,
process, formula, technique, method, trade secret or other intellectual property, whether or not patentable, whether or not copyrightable
(collectively, “Company Invention”) made, conceived, developed or first reduced to practice by Consultant, either
alone or jointly with others, while performing the Services hereunder. Consultant hereby assigns to the Company all of Consultant’s
right, title and interest in and to any such Company Inventions, which shall be the sole property of the Company. Consultant will execute
any documents necessary to perfect the assignment of such Inventions to the Company and to enable the Company to apply for, obtain, and
enforce patents or copyrights in any and all countries on such Company Inventions. Consultant hereby irrevocably designates the officers
of the Company as Consultant’s agent and attorney-in-fact to execute and file any such document and to do all lawful acts necessary
to apply for and obtain patents and copyrights, and to enforce the Company’s rights under this Section 6.

 

7.            Company
Authorization for Publication. Prior to Consultant’s submitting or disclosing for possible publication or dissemination
outside the Company any material prepared by Consultant that incorporates information that concerns the Company’s business or anticipated
research, Consultant agrees to deliver a copy of such material to the Chairman of the Board of Directors of the Company for review. Within
thirty (30) days following such submission, the Company agrees to notify Consultant in writing whether the Company believes such material
contains any Confidential Information related to the Services, and Consultant agrees to make such deletions and revisions as are reasonably
requested by the Company to protect its Confidential Information related to the Services. Consultant further agrees to obtain the written
consent of the Company prior to any review of such material by persons outside the Company.

 

    Exhibit A - 2

     

    

 

8.            Independent
Contractor.  The Company and Consultant mutually understand and agree that Consultant shall be at all times acting and
performing as an independent contractor. Nothing in this Agreement is intended to create an employer/employee relationship or a joint
venture relationship between the parties. The parties agree that Consultant is not eligible for any compensation, fringe benefits, pension,
workers’ compensation, sickness or health insurance benefits, or other similar benefits accorded employees of the Company. The parties
agree that the Company will not withhold any sums for income tax, unemployment insurance, social security or any other withholding pursuant
to any law or requirement of any governmental body on behalf of Consultant. Consultant acknowledges and agrees that the Company has no
obligation under local, state or federal laws regarding Consultant and that the total commitment and liability of the Company in regard
to any arrangement with, or work performed by, Consultant hereunder is to pay the fees and expenses pursuant to the provisions of this
Agreement. Consultant shall indemnify and hold the Company harmless from any and all loss, damage, claims, payments or liability arising
with respect to any such payment, withholdings and benefits, if any. Nothing in this Agreement is intended to allow the Company to exercise
control or direction over the manner or method by which Consultant performs the Services under the terms of Consultant’s engagement
hereunder.

 

9.            Non-Solicitation
or Hire of the Company Employees. During the Consultation Period and for one (1) year thereafter, Consultant shall
not encourage or solicit any employee of the Company to leave the Company for any reason or to accept employment with Consultant or any
other entity. As part of this restriction, Consultant shall not (a) interview or provide any input to any third party regarding any
such employee during such time period, or (b) retain or hire in any capacity, either individually or for any person or entity by
which Consultant may be engaged or with which Consultant may be affiliated, any person who is or was employed by the Company at any time
during the Consultation Period and six (6) months after the termination of such engagement.

 

10.         Non-Solicitation
of Non-Employees. During the Consultation Period and for one (1) year thereafter, Consultant shall not interfere
with or attempt to impair the relationship between the Company and any of its non-employee consultants and advisors, nor shall Consultant
attempt, directly or indirectly, to solicit, entice, hire or otherwise induce any non-employee consultant or advisor of the Company to
terminate association with the Company. The Company will not interfere with or attempt to impair the relationship between the Consultant
and any non-employee consultants and advisors during the Consultation Period and for one (1) year thereafter.

 

11.         Non-Competition.
During the Consultation Period and for one (1) year thereafter, Consultant shall not, with or without consideration, render services
in any capacity to any person, business, firm or corporation engaged in any business competitive with the business conducted or proposed
to be conducted by the Company during the Consultation Period. Consultant shall not become interested in any such business involved in
competitive activities with the Company, either directly or indirectly, as partner, stockholder, principal, member, employee, agent, trustee,
consultant, or any other relationship or capacity; provided, however, that such restriction shall not apply with respect to a less than
or equal to a one percent (1%) interest in any entity which is publicly traded and listed on a recognized securities exchange.

 

12.         Maintenance
of Records. During the Consultation Period and, until the expiration of five (5) years after the furnishing of
the Services pursuant to this Agreement, Consultant shall make available, upon written request of the Company or its designee, any records
maintained by Consultant regarding any of the Services performed hereunder by Consultant.

 

13.         No
Authority to Bind. Consultant shall have no power or authority to execute any agreements or contracts for or on behalf
of the Company nor to bind the Company in any other manner.

 

14.         Indemnification.
Consultant shall save, indemnify, defend and hold the Company harmless from any liability, claim, loss, damage, or expenses, including,
without limitation, reasonable attorney fees, arising from Consultant’s acts or omissions in the course of providing the Services.

 

    Exhibit A - 3

     

    

 

15.         Assignment.
Due to the personal nature of the Services, Consultant may not assign this Agreement. The Company may assign all rights and liabilities
under this Agreement to a subsidiary or an affiliate or to a successor to all or a substantial part of its business and assets without
the consent of Consultant. Subject to the foregoing, this Agreement will inure to the benefit of and be binding upon each of the heirs,
assigns and successors of the respective parties.

 

16.         Remedies.
Consultant acknowledges that the Company would have no adequate remedy at law to enforce Sections 5, through 14 hereof.
In the event of a violation of such sections, the Company shall have the right to obtain injunctive or other similar relief, as well as
any other relevant damages, without the requirement of posting bond or other similar measures.

 

17.         Notices.
All notices, requests, demands and other communications required or permitted hereunder shall be in writing and shall be mailed by registered
or certified mail, postage prepaid, sent by facsimile or electronic or otherwise delivered by hand, messenger or courier service addressed
to the address of such party set forth in the introductory paragraph of this Agreement or to such address directed by a party in writing.
Each such notice, request, demand or other communication shall for all purposes of this Agreement be treated as effective or having been
given (a) if delivered by hand, messenger or courier service, when delivered (or if sent via a nationally-recognized overnight courier
service, freight prepaid, specifying next-business-day delivery, one business day after deposit with the courier), or (b) if sent
via mail, at the earlier of its receipt or five (5) days after the same has been deposited in a regularly-maintained receptacle for
the deposit of the United States mail, addressed and mailed as aforesaid, or (c)  if sent via electronic mail, when directed to the
relevant electronic mail address, if sent during normal business hours of the recipient, or if not sent during normal business hours of
the recipient, then on the recipient’s next business day. In the event of any conflict between the Company’s books and records
and this Agreement or any notice delivered hereunder, the Company’s books and records will control absent fraud or error.

 

18.         Entire
Agreement. This Agreement together with the Separation Agreement shall constitute the entire agreement between the parties
and supersedes any and all other written or oral agreements between Consultant and the Company with respect to the subject matter of this
Agreement. If any provision of this Agreement shall be declared invalid, illegal or unenforceable, such provision shall be severed and
the remaining provisions shall continue in full force and effect. This Agreement may not be amended except by mutual written agreement
of the parties.

 

19.         Collection
Costs and Attorneys’ Fees. If a party shall fail to perform an obligation or otherwise breaches one or more of the terms
of this Agreement, the other party may recover from the non-performing breaching party all its costs (including actual attorneys’
and investigative fees) to enforce the terms of this Agreement.

 

20.         Governing
Law; Consent to Jurisdiction, Waiver of Jury Trial. This Agreement shall be governed by and construed in accordance with the
internal laws of the Commonwealth of Massachusetts, without regard to its principles of conflicts of laws. Each of the Parties hereto
irrevocably submits to the exclusive jurisdiction of the state and federal courts of the Commonwealth of Massachusetts for the purpose
of any suit, action, proceeding or judgment relating to or arising out of this Agreement and the transactions contemplated hereby. Service
of process in connection with any such suit, action or proceeding may be served on each Party hereto anywhere in the world by the same
methods as are specified for the giving of notices under this Agreement.  Each of the Parties hereto irrevocably consents to the
jurisdiction of any such court in any such suit, action or proceeding and to the laying of venue in such court.  Each Party hereto
irrevocably waives any objection to the laying of venue of any such suit, action or proceeding brought in such courts and irrevocably
waives any claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum.  EACH
OF THE PARTIES HERETO WAIVES ANY RIGHT TO REQUEST A TRIAL BY JURY IN ANY LITIGATION WITH RESPECT TO THIS AGREEMENT AND REPRESENTS THAT
COUNSEL HAS BEEN CONSULTED SPECIFICALLY AS TO THIS WAIVER. In addition, should it become necessary for the Company to seek to enforce
any of the covenants contained in this Agreement through any legal, administrative or alternative dispute resolution proceeding, Employee
shall reimburse the Company for its reasonable fees and expenses (legal costs, attorneys’ fees and otherwise) related thereto.

 

    Exhibit A - 4

     

    

 

21.         Counterparts/Electronic
Execution and Delivery. This Agreement may be executed in one or more counterparts and by facsimile or by electronic
delivery, each of which shall constitute an original and all of which together shall constitute one and the same instrument. Signatures
of the Parties transmitted by facsimile or via .pdf format shall be deemed to be their original signatures for all purposes. The words
 “execution,” “signed,” “signature,” and words of like import shall be deemed to include electronic
signatures or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as
a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for
in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the Massachusetts Uniform Electronic
Transactions Act, or any other similar state laws based on the Uniform Electronic Transactions Act. This Agreement and any signed agreement
or instrument entered into in connection with this Agreement, and any amendments hereto or thereto, to the extent delivered by means of
a facsimile machine or electronic mail (any such delivery, an “Electronic Delivery”), will be treated in all
manner and respects as an original agreement or instrument and will be considered to have the same binding legal effect as if it were
the original signed version thereof delivered in person. At the request of any Party hereto or to any such agreement or instrument, each
other Party hereto or thereto will re-execute original forms thereof and deliver them to all other Parties. No Party hereto or to any
such agreement or instrument will raise the use of Electronic Delivery to deliver a signature or the fact that any signature or agreement
or instrument was transmitted or communicated through the use of Electronic Delivery as a defense to the formation of a contract, and
each such Party forever waives any such defense, except to the extent such defense related to lack of authenticity.

 

Signatures
on the Following Page

 

    Exhibit A - 5

     

    

 

In
Witness Whereof, the Company and Consultant have made this Agreement effective as of the date first set forth above.

 

	THE COMPANY:	 	CONSULTANT:
	 	 	 
	NeuroBo Pharmaceuticals, Inc.	 	 
	 	 	 
	By:	 	 	 
	Name:	 Douglas J. Swirsky	 	Richard Kang, Ph.D.
	Title:	 Chairman of the Board	 	 

 

    Exhibit A - 6

     

    

 

Exhibit A

 

DESCRIPTION OF SERVICES

 

During the Consultation Period,
Consultant shall consult with the Company at such specific times and at such particular locations as Consultant and the Company mutually
determine from time to time on matters related to (i) the transition of Consultant’s prior role as Chief Executive Officer
and President of the Company; (ii) Consultant’s successor, service as an officer and member of the governing body of the Company’s
subsidiary, , NeuroBo Co., Ltd., until the election and qualification of Consultant’s successor, or until Employee’s
resignation or removal from such position at NeuroBo Co., Ltd.; and (iii) additional services that the Company may request of
Consultant from time to time.

 

    Exhibit A - 7Exhibit
10.4 

 

Employment
Agreement

 

THIS EMPLOYMENT AGREEMENT
(this “Agreement”) by and between NeuroBo Pharmaceuticals, Inc.,
a Delaware corporation (the “Company”), and Gil Price (the
“Executive”) is signed by the Company and the Executive and is entered into on and made effective as of November 3,
2021 (the “Effective Date”).

 

Recitals

 

Whereas,
the Company and the Executive are parties to that certain Consulting Agreement dated July 5, 2021 (collectively, the “Consulting
Agreement”), pursuant to which the Company retained the Executive as a consultant to the Company;

 

Whereas,
the board of directors of the Company (the “Board”) has determined that it is in the best interests of the Company
and its stockholders to employ the Executive on the Effective Date;

 

Whereas,
the Company and the Executive desire to enter into this Agreement to embody the terms of the Executive’s continued relationship
with the Company following the Effective Date; and

 

Whereas,
this Agreement shall represent the entire understanding and agreement between the parties with respect to the Executive’s employment
with the Company.

 

Agreement

 

Now,
Therefore, in consideration of the foregoing, and for other good and valuable consideration, including the respective covenants
and agreements set forth below, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

 

1.            Employment
Period.  On the Effective Date, the Executive’s consultancy relationship with the Company
shall terminate and the Company hereby agrees to employ the Executive, and the Executive hereby agrees to be employed by the Company,
subject to the terms and conditions of this Agreement, for the period commencing on the Effective Date and ending on the first (1st)
anniversary of the Effective Date (the “Initial Term”). The term of this Agreement will automatically be renewed
for a term of one (1) year (the “Renewal Term”) at the end of the Initial Term, provided that the Board
does not provide written notice to the Executive of the Company’s intention not to renew this Agreement at least sixty (60) days
prior to the expiration of the Initial Term. For purposes of this Agreement, “Employment Period” includes the
Initial Term and the Renewal Term thereafter, if applicable.

 

    	 	1	 

     

    

 

2.            Terms
of Employment.

 

(a)            Position
and Duties.

 

(i)            During
the Employment Period, the Executive shall initially serve as the Chief Medical Officer of the Company and beginning on the date that
Richard Kang ceases to be the Chief Executive Officer and President of the Company, the Executive shall transition to the President and
Chief Executive Officer of the Company, and in such other position or positions with the Company and its subsidiaries as are consistent
with the Executive’s position, and shall have such duties and responsibilities as are assigned to the Executive by the Board consistent
with the Executive’s position as the President and Chief Executive Officer, including serving as the Company’s principal executive
officer and principal financial and accounting officer. The Executive shall report to the Board. The Executive shall work remotely from
both the Executive’s home office and as reasonably requested from time to time at the Company’s principal executive offices
and such other locations as needed or reasonably requested from time to time by the Chairman of the Board.

 

(ii)           During
the Employment Period, and excluding any periods of vacation and sick leave to which the Executive is entitled, the Executive agrees to
devote reasonable attention and time during normal business hours and on a full-time basis to the business and affairs of the Company,
to discharge the responsibilities assigned to the Executive hereunder, and to use the Executive’s reasonable best efforts to perform
faithfully and efficiently such responsibilities. During the Employment Period it shall not be a violation of this Agreement for the Executive
to (A) be employed by the Company or any of its subsidiaries or Affiliates (as defined below); (B) serve on civic or charitable
boards, committees, or advisory boards; (C) deliver lectures, fulfill speaking engagements or teach at educational institutions;
(D) manage personal investments; (E) serve on the boards of directors of not-for-profit organizations; or (F) serve on
the boards of directors of not more than two (2) for-profit entities as approved in advance in writing by the Board, so long as such
activities do not interfere with the performance of the Executive’s responsibilities as an employee of the Company in accordance
with this Agreement. The Company and the Executive acknowledge and agree that this Agreement is not a breach of or conflict with the Consulting
Agreement and that the consultancy relationship contemplated by the Consulting Agreement shall terminate on the Effective Date and shall
be replaced by the employment relationship set forth in the terms and conditions of this Agreement and its attachments.

 

(b)            Compensation.

 

(i)            Base
Salary.  During the Employment Period, the Executive shall receive an annual base salary
(the “Annual Base Salary”) of $400,000 subject to applicable withholding taxes, which shall be paid in accordance
with the Company’s normal payroll practices for senior executive officers of the Company as in effect from time to time. During
the Employment Period, commencing with the review of base salaries in connection with the Company’s compensation program for the
2023 fiscal year, the Annual Base Salary shall be reviewed at least annually by the Board or the Compensation Committee of the Board (the
“Compensation Committee”). Any increase in the Annual Base Salary shall not serve to limit or reduce any other
obligation to the Executive under this Agreement. The Annual Base Salary shall not be reduced after any such increase (unless otherwise
agreed to by the Executive) and the term “Annual Base Salary” as utilized in this Agreement shall refer to the Annual Base
Salary as so increased or adjusted.

 

    	 	2	 

     

    

 

(ii)           Annual
Bonus. In addition to the Annual Base Salary, for each fiscal year ending during the Employment
Period, the Executive shall be eligible for an annual cash bonus (the “Annual Bonus”), as determined by the
Compensation Committee or the Board (in their sole and absolute discretion) based on the Company and the Executive achieving performance
goals and objectives for such calendar year as reasonably determined by the Compensation Committee, which value shall be up to 50% of
the Annual Base Salary actually paid to the Executive in such fiscal year and as determined in accordance with the policies and practices
generally applicable to other senior executive officers of the Company. The Annual Bonus, if any, will be subject to applicable payroll
deductions and withholdings. No amount of any Annual Bonus is guaranteed at any time, and, except as otherwise stated in Section 5(a)(i)(B),
the Executive must be an employee of the Company in good standing through the date the Annual Bonus is paid to be eligible to receive
an Annual Bonus. Each such Annual Bonus awarded to the Executive shall be paid sometime during the first seventy-five (75) days of the
fiscal year next following the fiscal year for which the Annual Bonus is awarded, unless the Executive shall elect, in compliance with
Treasury Regulation 1.409A-2(a), to defer the receipt of such Annual Bonus. For the avoidance of doubt, any Annual Bonus earned by the
Executive during the calendar year of 2021 shall be prorated by the number of days (or other measurement of time) during which the Executive
was employed by the Company in the calendar year of 2021.

 

(iii)         Option
Award. Subject to the terms of the Company’s 2021 Inducement Plan (the “Inducement
Plan”) and the form of stock option agreement issued thereunder, promptly following the Effective Date and approval by the
Board, the Company will issue the Executive a “nonstatutory stock option,” which is not intended to satisfy the requirements
of an “incentive stock option” as described in Section 422 of the Code (as defined below), to purchase (the “Option
Award”) 616,666 shares of the Company’s common stock (the “Shares”), as a material inducement
for Executive’s acceptance of employment with the Company. The Option Award shall include the following additional terms: (1) the
exercise price per share shall be equal to the Fair Market Value (as defined in the Inducement Plan) of a share of the Company’s
common stock on the date of grant of the Option Award; (2) subject to the Executive’s continued employment and the terms and
conditions of the Inducement Plan, the Shares subject to the Option Award shall vest and become exercisable as follows, 266,666 of the
Shares shall vest and become exercisable on the first anniversary of the Effective Date and 350,000 of the Shares shall vest and become
exercisable on the second anniversary of the Effective Date, subject to the Executive’s continuous service with the Company or an
Affiliate through such vesting dates; and (3) in the event that during the Employment Period the Company consummates a Change in
Control (as defined below) and the Option Award is not assumed, continued or substituted by the surviving corporation or acquiring corporation
(or the surviving or acquiring corporation’s parent company) in such Change in Control in the manner contemplated by Section 9(c)(i) of
the Inducement Plan, then 100% of the unvested Shares subject to the Option Award shall fully vest and become exercisable immediately
prior to the effectiveness of such Change in Control, subject to the Executive’s continued employment with the Company as of each
such date and as further provided in the terms and conditions of this Agreement, the Option Award and the Inducement Plan.

 

(iv)          Welfare
Benefit Plans.  During the Employment Period, the Executive and/or the Executive’s
family, as the case may be, shall be eligible for participation in and shall receive all benefits under welfare benefit plans, practices,
policies and programs provided by the Company and its Affiliates (including, without limitation, medical, prescription, dental, disability,
employee life, group life, accidental death and travel accident insurance plans and programs) made available to other senior executive
officers of the Company. Notwithstanding the foregoing, the Company may amend or discontinue any such welfare benefit plans, practices,
policies and programs at any time in its sole discretion.

 

    	 	3	 

     

    

 

(v)            Expenses.
During the Employment Period, the Executive shall be entitled to receive prompt reimbursement
for all reasonable expenses incurred by the Executive in accordance with the plans, practices, policies and programs of the Company.

 

(vi)          Vacation.
 During the Employment Period, the Executive shall be entitled to take vacation in accordance
with the Company’s applicable vacation policy as in effect from time to time for its senior executive officers. The Executive shall
also be entitled to all paid holidays given by the Company to its senior executive officers in accordance with the plans, practices, policies
and programs of the Company.

 

3.            Termination
of Employment.

 

(a)            Notwithstanding
Section 1, the Employment Period shall end upon the earliest to occur of: (i) the Executive’s death; (ii) a
Termination due to Disability (as defined below); (iii) a Termination for Cause (as defined below); (iv) the Termination Date
(as defined below) specified in connection with any exercise by the Company of its Termination Right (as defined below); (v) a Termination
for Good Reason (as defined below) by the Executive; (vi) the termination of this Agreement by Executive pursuant to Section 3(b);
or (vii) expiration of the Employment Period. Upon termination of the Executive’s employment with the Company for any reason,
the Executive will be deemed to have automatically resigned, effective as of the Termination Date, from any and all positions that the
Executive holds as an officer, director, manager and/or member of any governing body (or a committee thereof), in any case, of the Company
or any of its Affiliates.

 

(b)            This
Agreement may be terminated by the Executive at any time upon sixty (60) days prior written notice to the Company or upon such shorter
period as may be agreed upon between the Executive and the Board. Notwithstanding any other provision of this Agreement, in the event
of a termination by the Executive other than a Termination for Good Reason, the Company shall be obligated only to continue to pay the
Executive’s salary and provide other benefits provided by this Agreement up to the date of the termination.

 

(c)            Benefits
Payable Under Termination.

 

(i)            In
the event of the Executive’s death during the Employment Period or a Termination due to Disability, the Executive or the Executive’s
beneficiaries or legal representatives shall be provided the Unconditional Entitlements (as defined below), and any additional benefits
that are or become payable under any Company plan, policy, practice or program or any contract or agreement with the Company by reason
of the Executive’s death or Termination due to Disability.

 

(ii)           In
the event of the Executive’s Termination for Cause or termination by the Executive other than a Termination for Good Reason, the
Executive shall be provided the Unconditional Entitlements.

 

    	 	4	 

     

    

 

(iii)         In
the event of a Termination for Good Reason by the Executive or the exercise by the Company of the Company’s Termination Right, the
Executive shall be provided the Unconditional Entitlements and, subject to the Executive signing and delivering to the Company and not
subsequently revoking before the sixtieth (60th) day following the Termination Date, a general release of claims in favor of
the Company in a form substantially similar to the form attached hereto as Exhibit A,
with updates only for compliance with legal changes in the law (the “Release”), the Company shall provide the
Executive the Conditional Benefits (as defined below). Any and all amounts payable and benefits or additional rights provided to the Executive
upon a termination of the Executive’s employment pursuant to this Section 3(c) (other than the Unconditional Entitlements)
or the expiration of the Employment Period shall only be payable or provided if the Executive signs and delivers the Release and if the
Release becomes irrevocable prior to the sixtieth (60th) day following the Termination Date.

 

(d)            Unconditional
Entitlements. For purposes of this Agreement, the “Unconditional Entitlements”
to which the Executive may become entitled under Section 3(c) are as follows:

 

(i)            Earned
Amounts. The Earned Compensation (as defined below) shall be paid within thirty (30) days
following the termination of the Executive’s employment hereunder.

 

(ii)           Benefits.
 All benefits payable to the Executive under any employee benefit plans (including, without
limitation any pension plans or 401(k) plans) of the Company or any of its Affiliates applicable to the Executive at the time of
termination of the Executive’s employment with the Company and all amounts and benefits (other than the Conditional Benefits) which
are vested or which the Executive is otherwise entitled to receive under the terms of or in accordance with any plan, policy, practice
or program of, or any contract or agreement with, the Company, at or subsequent to the date of the Executive’s termination without
regard to the performance by the Executive of further services or the resolution of a contingency, shall be paid or provided in accordance
with and subject to the terms and provisions of such plans, it being understood that all such benefits shall be determined on the basis
of the actual date of termination of the Executive’s employment with the Company.

 

(iii)          Indemnities.
Any right which the Executive may have to claim a defense and/or indemnity for liabilities
to or claims asserted by third parties in connection with the Executive’s activities as an officer, director or employee of the
Company shall be unaffected by the Executive’s termination of employment (other than the Executive’s Termination for Cause)
and shall remain in effect in accordance with its terms.

 

(iv)          Medical
Coverage. The Executive shall be entitled to such continuation of health care coverage as
is required under, and in accordance with, applicable law or otherwise provided in accordance with the Company’s policies. The Executive
shall be notified in writing of the Executive’s rights to continue such coverage after the termination of the Executive’s
employment pursuant to this Section 3(d)(iv), provided that the Executive timely complies with the conditions to continue
such coverage. The Executive understands and acknowledges that the Executive is responsible to make all payments required for any such
continued health care coverage that the Executive may choose to receive (except to the extent additional rights are provided upon Executive’s
qualifying to receive Conditional Benefits).

 

    	 	5	 

     

    

 

(v)            Business
Expenses.  The Executive shall be entitled to reimbursement, in accordance with the Company’s
policies regarding expense reimbursement as in effect from time to time, for all business expenses incurred by the Executive prior to
the termination of the Executive’s employment.

 

(vi)          Stock
Options/Equity Awards.  The Executive’s rights with respect to any stock option, restricted
stock or other equity award granted to the Executive by the Company shall be governed by the terms and provisions of the Inducement Plan
or equity incentive plan, the applicable Original Stock Option Award Documents or Original Award Documents (each as defined below).

 

(e)            Conditional
Benefits.  For purposes of this Agreement, the “Conditional Benefits”
to which the Executive may become entitled are as follows:

 

(i)            Severance
Amount.  The Severance Amount (as defined below) will be subject to all applicable withholdings
and will be payable by the Company to the Executive in three (3) equal monthly installments beginning on the first regular payroll
date following the date that the Release becomes effective and irrevocable or, if any component of the Severance Amount is subject to
Section 409A (as defined below), beginning on the first regular Company payroll date after the sixtieth (60th) day following
the Termination Date.

 

(ii)           Additional
Distribution Rules. Notwithstanding any other payment date or schedule provided in this Agreement
to the contrary, if the Executive is deemed on the Termination Date of the Executive’s employment to be a “specified employee”
within the meaning of that term under Section 409A of the Code and the regulations thereunder (“Section 409A”),
then each of the following shall apply:

 

(A)            With
regard to any payment that is considered “nonqualified deferred compensation” under Section 409A and payable on account
of a “separation from service” (within the meaning of Section 409A and as provided in Section 3(h) of
this Agreement), such payment shall not be made prior to the date which is the earlier of (1) the expiration of the six (6)-month
period measured from the date of the Executive’s “separation from service,” and (2) the date of the Executive’s
death (the “Delay Period”) to the extent required under Section 409A. Upon the expiration of the Delay
Period, all payments delayed pursuant to this Section 3(e)(ii)(A) (whether they would have otherwise been payable in
a single sum or in installments in the absence of such delay) shall be paid to the Executive in a lump sum, and all remaining payments
due under this Agreement shall be paid or provided in accordance with the normal payment dates specified for them herein; and

 

(B)            To
the extent that benefits to be provided during the Delay Period are considered “nonqualified deferred compensation” under
Section 409A provided on account of a “separation from service,” the Executive shall pay the cost of such benefits during
the Delay Period, and the Company shall reimburse the Executive, to the extent that such costs would otherwise have been paid or reimbursed
by the Company or to the extent that such benefits would otherwise have been provided by the Company at no cost to the Executive, for
the Company’s share of the cost of such benefits upon expiration of the Delay Period, and any remaining benefits shall be paid,
reimbursed or provided by the Company in accordance with the procedures specified herein.

 

    	 	6	 

     

    

 

The foregoing provisions of
this Section 3(e)(ii)(A) and (B) shall not apply to any payments or benefits that are excluded from the definition
of “nonqualified deferred compensation” under Section 409A, including, without limitation, payments excluded from the
definition of “nonqualified deferred compensation” on account of being separation pay due to an involuntary separation from
service under Treasury Regulation 1.409A-1(b)(9)(iii) or on account of being a “short-term deferral” under Treasury Regulation
1.409A-1(b)(4).

 

(f)             Definitions.
For purposes of this Agreement, the following terms shall have the meanings ascribed to them below:

 

(i)            “Affiliate”
means any corporation, partnership, limited liability company, trust, or other entity which directly, or indirectly through one or more
intermediaries, controls, is under common control with, or is controlled by, the Company.

 

(ii)            “Change
in Control” means the occurrence, in a single transaction or in a series of related
transactions, of any one or more of the following events:

 

(A)            any
Exchange Act Person (as defined below) becomes the Owner (as defined below), directly or indirectly, of securities of the Company representing
more than 50% of the combined Voting Power (as defined below) of the Company’s then outstanding securities other than by virtue
of a merger, consolidation or similar transaction. Notwithstanding the foregoing, a Change in Control will not be deemed to occur (1) in
connection with the issuance of any securities of the Company as part of a licensing transaction, joint venture or strategic partnership
to which the Company is party; (2) on account of the acquisition of securities of the Company directly from the Company; (3) on
account of the acquisition of securities of the Company by an investor, any Affiliate thereof or any other Exchange Act Person that acquires
the Company’s securities in a transaction or series of related transactions the primary purpose of which is to obtain financing
for the Company through the issuance of equity securities; (4) on account of any acquisition of securities of the Company by (y) any
individual who is, on the Effective Date, either an executive officer or a member of the Board and/or any entity in which an executive
officer or member of the Board has a direct or indirect interest (whether in the form of voting rights or participation in profits or
capital contributions) of more than 50% or (z) any entity (or its Affiliates) that owns at least 9.9% of the combined Voting Power
of the Company’s outstanding securities as of the Effective Date (collectively, the “Incumbent Entities”);
(5) on account of the Incumbent Entities continuing to hold shares that come to represent more than 50% of the combined Voting Power
of the Company’s then outstanding securities as a result of the conversion of any class of the Company’s securities into another
class of the Company’s securities having a different number of votes per share pursuant to the conversion provisions set forth in
the Company’s Third Amended and Restated Certificate of Incorporation; or (6) solely because the level of Ownership (as defined
below) held by any Exchange Act Person (the “Subject Person”) exceeds the designated percentage threshold of
the outstanding Voting Securities (as defined below) as a result of a repurchase or other acquisition of Voting Securities by the Company
reducing the number of shares outstanding, provided that if a Change in Control would occur (but for the operation of this sentence) as
a result of the acquisition of Voting Securities by the Company, and after such share acquisition, the Subject Person becomes the Owner
of any additional Voting Securities that, assuming the repurchase or other acquisition had not occurred, increases the percentage of the
then outstanding Voting Securities Owned by the Subject Person over the designated percentage threshold, then a Change in Control will
be deemed to have occurred;

 

    	 	7	 

     

    

 

(B)            a
merger, consolidation or similar transaction involving (directly or indirectly) the Company is consummated and, immediately after the
consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do not Own
(as defined below), directly or indirectly, either (1) outstanding Voting Securities representing more than 50% of the combined outstanding
Voting Power of the surviving entity in such merger, consolidation or similar transaction or (2) more than 50% of the combined outstanding
Voting Power of the parent of the surviving entity in such merger, consolidation or similar transaction, in each case in substantially
the same proportions as their Ownership of the outstanding Voting Securities of the Company immediately prior to such transaction; provided,
however, that a merger, consolidation or similar transaction will not constitute a Change in Control under this prong of the definition
if the outstanding Voting Securities representing more than 50% of the combined Voting Power of the surviving entity or its parent are
owned by the Incumbent Entities;

 

(C)            a
sale, lease, exclusive license or other disposition of all or substantially all of the consolidated assets of the Company and its subsidiaries
is consummated, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company
and its subsidiaries to an entity, more than 50% of the combined Voting Power of the Voting Securities of which are Owned by stockholders
of the Company in substantially the same proportions as their Ownership of the outstanding Voting Securities of the Company immediately
prior to such sale, lease, license or other disposition; provided, however, that a sale, lease, exclusive license or other disposition
of all or substantially all of the consolidated assets of the Company and its subsidiaries will not constitute a Change in Control under
this prong of the definition if the outstanding Voting Securities representing more than 50% of the combined Voting Power of the acquiring
entity or its parent are owned by the Incumbent Entities; or

 

(D)            individuals
who, on the Effective Date, are members of the Board (the “Incumbent Board”) cease for any reason to constitute
at least a majority of the members of the Board; provided, however, that if the appointment or election (or nomination for election)
of any new Board member was approved or recommended by a majority vote of the members of the Incumbent Board then still in office, such
new member will, for purposes of this Agreement, be considered as a member of the Incumbent Board.

 

Notwithstanding the foregoing
definition, the term Change in Control will not include a sale of assets, merger or other transaction effected exclusively for the purpose
of changing the domicile of the Company; moreover, in the case of any payment or benefit that constitutes nonqualified deferred compensation
under Section 409A, if necessary in order to ensure that the Executive does not incur liability for additional tax under Section 409A,
a transaction (or series of related transactions) shall constitute a Change in Control only if, in addition to satisfying the foregoing
definition, such transaction (or series of related transactions) also satisfies the definition of a “change in control event”
under Treasury Regulation 1.409A-3(i)(5).

 

    	 	8	 

     

    

 

(iii)         “Code”
means the Internal Revenue Code of 1986, as amended and the rules and regulations promulgated thereunder.

 

(iv)          “Earned
Compensation” means any Annual Base Salary earned, but unpaid, for services rendered
to the Company on or prior to the date on which the Employment Period ends pursuant to Section 3(a) (but excluding any
salary and interest accrued thereon payment of which has been deferred).

 

(v)           “Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and
regulations promulgated thereunder.

 

(vi)          “Exchange
Act Person” means any natural person, entity or “group” (within the meaning
of Section 13(d) or 14(d) of the Exchange Act), except that “Exchange Act Person” will not include (A) the
Company or any subsidiary of the Company; (B) any employee benefit plan of the Company or any subsidiary of the Company or any trustee
or other fiduciary holding securities under an employee benefit plan of the Company or any subsidiary of the Company; (C) an underwriter
temporarily holding securities pursuant to a registered public offering of such securities; (D) an entity Owned, directly or indirectly,
by the stockholders of the Company in substantially the same proportions as their Ownership of stock of the Company; or (E) any natural
person, entity or “group” (within the meaning of Section 13(d) or 14(d) of the Exchange Act) that, as of the
Effective Date, is the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined Voting Power
of the Company’s then outstanding securities.

 

(vii)         “Original
Award Documents” means, with respect to any restricted stock or other equity award,
the terms and provisions of the award agreement related to and the Equity Incentive Plan or applicable other Plan governing such restricted
stock or other equity award, each as in effect on the Termination Date.

 

(viii)        “Original
Stock Option Award Documents” means, with respect to any stock option, the terms and
provisions of the award agreement and Plan pursuant to which such stock option was granted, each as in effect on the Termination Date.

 

(ix)          “Own,”
 “Owned,” “Owner,” “Ownership” means a person or entity
will be deemed to “Own,” to have “Owned,” to be the “Owner” of, or to have acquired “Ownership”
of securities if such person or entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise,
has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities.

 

(x)           “Person”
shall have the same meaning as ascribed to such term in Section 3(a)(9) of the Exchange Act, as supplemented by Section 13(d)(3) of
the Exchange Act, and shall include any group (within the meaning of Rule 13d-5(b) under the Exchange Act); provided that Person
shall not include (A) the Company or any of its Affiliates, or (B) any employee benefit plan (including an employee stock ownership
plan or employee stock purchase plan) sponsored by the Company or any of its Affiliates.

 

(xi)          “Severance
Amount” means an amount equal to $100,000.

 

    	 	9	 

     

    

 

(xii)        “Termination
for Cause” means a termination of the Executive’s employment by the Company due
to (A) an act or acts of dishonesty undertaken by the Executive and intended to result in substantial gain or personal enrichment
to the Executive at the expense of the Company; (B) unlawful conduct or gross misconduct that is willful and deliberate on the Executive’s
part in the performance of the Executive’s employment duties and that, in either event, is injurious to the Company; (C) the
Executive’s conviction of (or plea of no contest to) any felony or a misdemeanor involving moral turpitude, deceit, dishonesty or
fraud, or any conduct by the Executive that results in material injury or reputational harm to the Company or any of its subsidiaries
and affiliates; (D) breach by the Executive of the Executive’s fiduciary obligations as an officer or director of the Company;
(E) a persistent failure by the Executive to perform the duties and responsibilities of the Executive’s employment hereunder,
which is not remedied by the Executive within thirty (30) days after the Executive’s receipt of written notice from the Company
of such failure; or (F) material breach of any terms and conditions of this Agreement by Executive, which breach has not been cured
by the Executive within ten (10) days after written notice thereof to Executive from the Company. For the purposes of this Section 3(f)(xii),
any act, or failure to act, based upon authority given pursuant to a resolution duly adopted by the Board shall be conclusively presumed
to be done, or omitted to be done, by the Executive in good faith and in the best interests of the Company.

 

(xiii)       “Termination
Date” means the earlier to occur of (A) the date the Company specifies in writing
to the Executive in connection with the exercise of its Termination Right; (B) the date on which the Employment Period expires as
a result of the Company’s decision not to renew this Agreement beyond the Initial Term or at the end of the Renewal Term; or (C) the
date the Executive specifies in writing to the Company in connection with any notice to effect a Termination for Good Reason. Notwithstanding
the foregoing, a termination of employment will not be deemed to have occurred for purposes of any provision of this Agreement providing
for the payment of any amounts or benefits subject to Section 409A upon or following a termination of employment unless such termination
is also a “separation from service” (within the meaning of Section 409A), and notwithstanding anything contained herein
to the contrary, the date on which such separation from service takes place will be the Termination Date.

 

(xiv)        “Termination
due to Disability” means a termination of the Executive’s employment by the Company
because the Executive has been incapable, after reasonable accommodation, of substantially fulfilling the positions, duties, responsibilities
and obligations set forth in this Agreement because of physical, mental or emotional incapacity resulting from injury, sickness or disease
for a period of (A) six (6) consecutive months or (B) an aggregate of nine (9) months (whether or not consecutive)
in any twelve (12) month period. Any question as to the existence, extent or potentiality of the Executive’s disability shall be
determined by a qualified physician selected by the Company with the consent of the Executive, which consent shall not be unreasonably
withheld. The Executive or the Executive’s legal representatives or any adult member of the Executive’s immediate family shall
have the right to present to such physician such information and arguments as to the Executive’s disability as he, she or they deem
appropriate, including the opinion of the Executive’s personal physician.

 

    	 	10	 

     

    

 

(xv)         “Termination
for Good Reason” means a termination of the Executive’s employment by the Executive
within thirty (30) days of the Company’s failure to cure, in accordance with the procedures set forth below, any of the following
events: (A) a reduction in Executive’s Annual Base Salary as in effect immediately prior to such reduction without Executive’s
written consent, unless such reduction is made pursuant to an across the board reduction applicable to all senior executives of the Company;
or (B) a material breach of any material provision of this Agreement by the Company to which the Executive shall have delivered a
written notice to the Board within forty-five (45) days of the Executive’s having actual knowledge of the occurrence of one of such
events stating that the Executive intends to commence a Termination for Good Reason and specifying the factual basis for such termination,
and such event, if capable of being cured, shall not have been cured within twenty-one (21) days of the receipt of such notice. Notwithstanding
the foregoing, a termination shall not be treated as a Termination for Good Reason if the Executive shall have consented in writing to
the occurrence of the event giving rise to the claim of Termination for Good Reason.

 

(xvi)        “Termination
Right” means the right of the Company, in its sole, absolute and unfettered discretion,
to terminate the Executive’s employment under this Agreement or not to renew this Agreement beyond the Initial Term or at the end
of the Renewal Term for any reason or no reason whatsoever. For the avoidance of doubt, any Termination for Cause effected by the Company
shall not constitute the exercise of its Termination Right.

 

(xvii)      “Voting
Power” means such number of Voting Securities as shall enable the holders thereof to
cast all the votes which could be cast in an annual election of directors of a company.

 

(xviii)     “Voting
Securities” means all securities entitling the holders thereof to vote in an annual
election of directors of a company.

 

(g)            Conflict
with Plans. As permitted under the terms of the Inducement Plan or any other equity incentive
plan, the Company and the Executive agree that the definitions of Termination for Cause or Termination for Good Reason set forth in this
Section 3 shall apply in place of any similar definition or comparable concept applicable under the Inducement Plan or any
other equity incentive plan (or any similar definition in any successor plan).

 

    	 	11	 

     

    

 

(h)            Section 409A.
 It is intended that payments and benefits under this Agreement either be excluded from or comply
with the requirements of Section 409A and the guidance issued thereunder and, accordingly, to the maximum extent permitted, this
Agreement shall be interpreted consistent with such intent. In the event that any provision of this Agreement is subject to but fails
to comply with Section 409A, the Company may revise the terms of the provision to correct such noncompliance to the extent permitted
under any guidance, procedure or other method promulgated by the Internal Revenue Service now or in the future or otherwise available
that provides for such correction as a means to avoid or mitigate any taxes, interest or penalties that would otherwise be incurred by
the Executive on account of such noncompliance. Provided, however, that in no event whatsoever shall the Company be liable for
any additional tax, interest or penalty imposed upon or other detriment suffered by the Executive under Section 409A or damages for
failing to comply with Section 409A. Solely for purposes of determining the time and form of payments due the Executive under this
Agreement (including any payments due under Sections 3(c) or 5) or otherwise in connection with the Executive’s
termination of employment with the Company, the Executive shall not be deemed to have incurred a termination of employment unless and
until the Executive shall incur a “separation from service” within the meaning of Section 409A. The parties agree, as
permitted in accordance with the final regulations thereunder, a “separation from service” shall occur when the Executive
and the Company reasonably anticipate that the Executive’s level of bona fide services for the Company (whether as an employee or
an independent contractor) will permanently decrease to no more than forty (40) percent of the average level of bona fide services performed
by the Executive for the Company over the immediately preceding thirty-six (36) months (or the period of Executive’s employment
if Executive has been employed with the Company less than thirty-six (36) months at the time of the Executive’s termination). The
determination of whether and when a separation from service has occurred shall be made in accordance with this subparagraph and in a manner
consistent with Treasury Regulation 1.409A-1(h). All reimbursements and in-kind benefits provided under this Agreement shall be made or
provided in accordance with the requirements of Section 409A to the extent that such reimbursements or in-kind benefits are subject
to Section 409A, including, where applicable, the requirements that (i) any reimbursement is for expenses incurred during the
Executive’s lifetime (or during a shorter period of time specified in this Agreement); (ii) the amount of expenses eligible
for reimbursement (and the in-kind benefits to be provided) during a calendar year may not affect the expenses eligible for reimbursement
(and the in-kind benefits to be provided) in any other calendar year; (iii) the reimbursement of an eligible expense will be made
on or before the last day of the calendar year following the year in which the expense is incurred; and (iv) the right to reimbursement
(or in-kind benefits) is not subject to set off or liquidation or exchange for any other benefit. For purposes of Section 409A, the
Executive’s right to any installment payments under this Agreement shall be treated as a right to receive a series of separate and
distinct payments. Whenever a payment under this Agreement specifies a payment period with reference to a number of days (e.g.,
 “payment shall be made within ninety (90) days following the date of termination”), the actual date of payment within the
specified period shall be within the sole discretion of the Company.

 

4.            Executive
Remedy. The Executive acknowledges and agrees that the payment and rights provided under Section 3
are fair and reasonable, and are the Executive’s sole and exclusive remedy, in lieu of all other remedies at law or in equity, for
termination of the Executive’s employment by the Company upon exercise of its Termination Right pursuant to this Agreement or upon
a Termination for Good Reason.

 

5.            Additional
Payments Following a Change in Control.

 

(a)            If
within twelve (12) months following or three (3) months prior to the effective date of a Change in Control: (i) the Executive
effects a Termination for Good Reason; or (ii) the Company terminates the Executive’s employment other than due to the Executive’s
death, a Termination due to a Disability or a Termination for Cause:

 

(i)            the
Company shall pay to the Executive, in a lump sum in cash within thirty (30) days after the later of the Termination Date or the effective
date of such Change in Control, the aggregate of the following amounts (which shall be paid to the Executive in lieu of the Severance
Amount):

 

(A)            the
Unconditional Entitlements, and

 

    	 	12	 

     

    

 

(B)            the
amount equal to the product of 1 times the sum of (y) the Annual Base Salary as in effect as of the Termination Date, and (z) an
amount equal to the target bonus for the Executive for the then current fiscal year; and

 

(ii)           the
Company shall provide the Executive the Conditional Benefits minus the Severance Amount.

 

(b)            If
any payment or benefit (whether or not pursuant to this Agreement) the Executive would receive in connection with a Change in Control
from the Company or otherwise (the “Payment”) would (i) constitute a “parachute payment” within
the meaning of Section 280G of the Code, and (ii) but for this paragraph, be subject to the excise tax imposed by Section 4999
of the Code (the “Excise Tax”), then the Executive shall have the option to select one of the following two
alternative forms of payment: (A) payment in full of the entire amount of the Payment, or (B) payment of only a part of the
Payment so that the Executive receives the largest payment possible without the imposition of the Excise Tax (a “Reduced Payment”).
If the Executive elects to receive a Reduced Payment, the reduction in payments and/or benefits shall occur in the following order: (A) reduction
of cash payments in the reverse chronological order in which otherwise payable; (B) cancellation of accelerated vesting of equity
awards other than stock options; (C) cancellation of accelerated vesting of stock options; and (D) reduction of other benefits
paid to the Executive in the reverse chronological order in which otherwise payable. In the event that acceleration of compensation from
the Executive’s equity awards is to be reduced, such acceleration of vesting shall be canceled in the reverse order of the date
of grant and, in the case of a particular grant, in the reverse chronological order in which the grant would otherwise vest.

 

(c)            The
independent registered public accounting firm engaged by the Company for general audit purposes as of the day prior to the effective date
of the Change in Control, or a nationally recognized law firm, shall make all determinations required to be made under this Section 5.
If the independent registered public accounting firm or nationally recognized law firm so engaged by the Company is serving as accountant
or auditor for the individual, entity or group effecting the Change in Control, the Company shall appoint an independent registered public
accounting firm or nationally recognized law firm to make the determinations required hereunder. The Company shall bear all expenses with
respect to the determinations by such independent registered public accounting firm required to be made hereunder.

 

(d)            The
independent registered public accounting firm or law firm engaged to make the determinations hereunder shall provide its calculations,
together with detailed supporting documentation, to the Company and the Executive within fifteen (15) calendar days after the date on
which Executive’s right to a Payment is triggered (if requested at that time by the Company or Executive) or such other time as
requested by the Company or Executive. Any good faith determinations of the accounting firm or law firm made hereunder shall be final,
binding and conclusive upon the Company and Executive.

 

    	 	13	 

     

    

 

6.           Confidentiality.

 

(a)            Confidentiality.
 Without the prior written consent of the Company, except (y) as reasonably necessary in
the course of carrying out the Executive’s duties hereunder or (z) to the extent required by an order of a court having competent
jurisdiction or under subpoena from an appropriate government agency, the Executive shall not disclose any Confidential Information (as
defined below) unless such Confidential Information has been previously disclosed to the public by the Company or has otherwise become
available to the public (other than by reason of the Executive’s breach of this Section 6(a)). The term “Confidential
Information” shall include, but shall not be limited to: (i) trade secrets, inventions, mask works, ideas, processes,
formulas, compositions of matter, models, methods, software in source or object code versions, data and databases, programs, drawings,
other works of authorship, know-how, improvements, discoveries, developments, designs and techniques and any other proprietary technology,
whether or not patentable or protectable by copyright, and all intellectual property rights therein; (ii) information regarding research,
development, new products, marketing and selling, business plans, budgets and unpublished financial statements, licenses, prices and costs,
margins, discounts, credit terms, pricing and billing policies, quoting procedures, methods of obtaining business, forecasts, future plans
and potential strategies, financial projections and business strategies, operational plans, financing and capital-raising plans, activities
and agreements, internal services and operational manuals, methods of conducting business of the Company, suppliers and supplier information,
and purchasing; (iii) information regarding customers and potential customers of the Company, including customer lists, names, representatives,
their needs or desires with respect to the types of products or services offered by the Company, proposals, bids, contracts and their
contents and parties, the type and quantity of products and services provided or sought to be provided to customers and potential customers
of the Company and other non-public information relating to customers and potential customers; (iv) information regarding any of
the Company’s business partners and their services, including names, representatives, proposals, bids, contracts and their contents
and parties, the type and quantity of products and services received by the Company, and other non-public information relating to business
partners; (v) information regarding personnel, employee lists, compensation, and employee skills; and (vi) any other non-public
information which a competitor of the Company could use to the competitive disadvantage of the Company. Effective as of the Executive’s
termination of employment with the Company or at any point prior on request of the Company, the Executive shall immediately return to
the Company all of the Confidential Information, including copies, reproductions and summaries thereof, in the Executive’s possession
and shall erase all such Confidential Information from all media in the Executive’s possession, and, if the Company so requests,
shall certify in writing that the Executive has done so. All of the Confidential Information is and shall remain the property of the Company
and its Affiliates.

 

(b)            Company
Property.  Promptly following the Executive’s termination of employment or as otherwise
requested by the Company, the Executive shall return to the Company all property of the Company, and all copies thereof in the Executive’s
possession or under the Executive’s control, except that the Executive may retain the Executive’s personal notes, diaries,
rolodexes, mobile devices, calendars and electronic calendars, and correspondence of a personal nature.

 

    	 	14	 

     

    

 

(c)            Nonsolicitation.
The Executive agrees that, while the Executive is employed by the Company and during the one
(1)-year period following the Executive’s termination of employment with the Company (the “Restricted Period”),
the Executive shall not directly or indirectly (i) solicit any individual who is, on the Termination Date (or was, during the six
(6)-month period prior to the Termination Date), employed by the Company or its Affiliates to terminate or refrain from renewing or extending
such employment or to become employed by or become a consultant to any other individual or entity other than the Company or its Affiliates
or (ii) induce or attempt to induce any customer or investor (in each case, whether former, current or prospective), supplier, licensee
or other business relation of the Company or any of its Affiliates to cease doing business with the Company or such Affiliate, or in any
way interfere with the relationship between any such customer, investor, supplier, licensee or business relation, on the one hand, and
the Company or any of its Affiliates, on the other hand. Any payments owed to Executive at time of separation as described herein shall
be contingent upon Executive’s compliance with the post-employment nonsolicitation provisions.

 

(d)            Noncompetition.
The Executive agrees that, during the Restricted Period, the Executive shall not be employed by, serve as a consultant to, or otherwise
assist or directly or indirectly provide services to a Competitor (as defined below). For purposes of this paragraph, services provided
by others shall be deemed to have been provided by the Executive to Competitor if the Executive had material supervisory responsibilities
with respect to the provision of such services. The term “Competitor” means any enterprise (including a person,
firm, business, division, or other unit, whether or not incorporated) that is engaged or actively preparing to engage in any business
in which the Company is engaged or in which the Company has actively planned to engage immediately prior to the termination of the Executive’s
employment with the Company.

 

(e)            Equitable
Remedies. The Executive acknowledges that the Company would be irreparably injured by a violation
of this Section 6 and the Executive agrees that the Company, in addition to any other remedies available to it for such
breach or threatened breach, on meeting the standards required by law, shall be entitled to a preliminary injunction, temporary restraining
order, or other equivalent relief, restraining the Executive from any actual or threatened breach of this Section 6. If a
bond is required to be posted in order for the Company to secure an injunction or other equitable remedy, the parties agree that said
bond need not be more than a nominal sum.

 

(f)             Employee
Proprietary Information and Inventions Assignment. The terms of that certain Employee Proprietary
Information, Inventions Assignment Agreement between the Executive and the Company dated as of the Effective Date (the “Invention
Assignment Agreement”) are hereby incorporated by reference. To the extent that there are any conflicts between the terms
and conditions of the Invention Assignment Agreement and this Agreement, the terms and conditions of this Agreement shall control. All
non-conflicting terms of the Invention Assignment Agreement are hereby expressly preserved. In the event of any conflict between this
Agreement and the provisions of the Consulting Agreement, the terms and conditions of this Agreement shall control. All non-conflicting
terms of the Consulting Agreement are hereby expressly preserved and will remain in full force and effect following any termination of
the Executive’s employment with the Company.

 

(g)            Severability;
Blue Pencil. The Executive acknowledges and agrees that the Executive has had the opportunity
to seek advice of counsel in connection with this Agreement and the restrictive covenants contained herein are reasonable in geographical
scope, temporal duration and in all other respects. If it is determined that any provision of this Section 6 is invalid or
unenforceable, the remainder of the provisions of this Section 6 shall not thereby be affected and shall be given full effect,
without regard to the invalid portions. If any court or other decision-maker of competent jurisdiction determines that any of the covenants
in this Section 6 is unenforceable because of the duration or geographic scope, of such provision, then after such determination
becomes final and unappealable, the duration or scope of such provision, as the case may be, shall be reduced so that such provision becomes
enforceable, and in its reduced form, such provision shall be enforced.

 

    	 	15	 

     

    

 

7.            Successors.

 

(a)            This
Agreement is personal to the Executive and without the prior written consent of the Company shall not be assignable by the Executive otherwise
than by will or the laws of descent and distribution. This Agreement shall inure to the benefit of and be enforceable by the Executive’s
legal representatives.

 

(b)            This
Agreement shall inure to the benefit of and be binding upon the Company and its successors and assigns and any party acting in the form
of a receiver or trustee capacity.

 

(c)            The
Company will require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially
all of the business and/or assets of the Company to assume expressly and agree to perform this Agreement in the same manner and to the
same extent that the Company would be required to perform it if no such succession had taken place. As used in this Agreement, “Company”
shall mean the Company as hereinbefore defined and any successor to its business and/or assets as aforesaid which assumes and agrees to
perform this Agreement by operation of law, or otherwise.

 

8.            Miscellaneous.

 

(a)            This
Agreement shall be construed, and the rights and obligations of the parties hereunder determined, in accordance with the substantive laws
of the State of Delaware, without regard to its conflict-of-laws principles.  For the purposes of any suit, action or proceeding
based upon, arising out of or relating to this Agreement or the negotiation, execution or performance hereof, the parties hereby expressly
submit to the jurisdiction of all federal and state courts sitting within the confines of the State of Delaware (the “Venue
Area”) and consent that any order, process, notice of motion or other application to or by any such court or a judge thereof
may be served within or without such court’s jurisdiction by registered mail or by personal service in accordance with Section 8(b). 
The parties agree that such courts shall have the exclusive jurisdiction over any such suit, action or proceeding commenced by either
or both of said parties.  Each party hereby irrevocably waives any objection that it may now or hereafter have to the laying of venue
of any suit, action or proceeding based upon, arising out of or relating to this Agreement or the negotiation, execution or performance
hereof, brought in any federal or state court sitting within the confines of the Venue Area and hereby further irrevocably waives any
claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum. The captions of this
Agreement are not part of the provisions hereof and shall have no force or effect. This Agreement may not be amended or modified otherwise
than by a written agreement executed by the parties hereto or their respective successors and legal representatives.

 

    	 	16	 

     

    

 

(b)            Any
notices required hereunder shall be in writing and shall be deemed effectively given: (i) upon personal delivery to the party to
be notified, (ii) when sent by electronic mail or confirmed facsimile if sent during normal business hours of the recipient, and
if not, then on the next business day, (iii) five (5) days after having been sent by registered or certified mail, return receipt
requested, postage prepaid, or (iv) one (1) day after deposit with a nationally- recognized overnight courier, specifying next-day
delivery, with written verification of receipt. All communications shall be sent to the Company at its primary office location and to
the Executive at Executive’s address as listed on the Company payroll or (if notice is given prior to the Executive’s termination
of employment) to the Executive’s Company-issued email address, or at such other address as the Company or the Executive may designate
by ten (10) days’ advance written notice to the other.

 

(c)            The
invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision
of this Agreement.

 

(d)            The
Company hereby agrees to indemnify the Executive and hold the Executive harmless to the extent provided under the Third Amended and Restated
Certificate of Incorporation of the Company, the Second Amended and Restated Bylaws of the Company and the Indemnification Agreement entered
by and between the Company and the Executive (the “Indemnification Agreement”) against and in respect of any
and all actions, suits, proceedings, claims, demands, judgments, costs, expenses (including reasonable attorney’s fees), losses,
and damages resulting from the Executive’s good faith performance of the Executive’s duties and obligations with the Company.
This obligation shall survive the termination of the Executive’s employment with the Company.

 

(e)            From
and after the Effective Date, the Company shall cover the Executive under directors’ and officers’ liability insurance both
during and, while potential liability exists, after the Employment Period in the same amount and to the same extent as the Company covers
its other executive officers and directors.

 

(f)             The
Company may withhold from any amounts payable under this Agreement such Federal, state, local or foreign taxes that the Company determines
are required to be withheld pursuant to any applicable law or regulation.

 

(g)            The
Executive’s or the Company’s failure to insist upon strict compliance with any provision of this Agreement or the failure
to assert any right the Executive or the Company may have hereunder shall not be deemed to be a waiver of such provision of right or any
other provision or right of this Agreement.

 

    	 	17	 

     

    

 

(h)            This
Agreement, the Invention Assignment Agreement, the Indemnification Agreement, the Consulting Agreement, the Original Award Documents,
the Original Stock Option Award Documents and all agreements, documents, instruments, schedules, exhibits or certificates prepared in
connection herewith, and as of the Effective Date represent the entire understanding and agreement between the parties with respect to
the subject matter hereof, supersede all prior understandings, agreements or negotiations between such parties, whether written or oral,
and may be amended, supplemented or changed only by an agreement in writing which makes specific reference to this Agreement or the agreement
or document delivered pursuant hereto, as the case may be, and which is signed by the party against whom enforcement of any such amendment,
supplement or modification is sought. If any of the terms and conditions of this Agreement conflict with the terms and conditions of the
Original Award Documents and the Original Stock Option Award Documents, the terms and conditions of this Agreement shall control. All
non-conflicting terms of the Original Award Documents and the Original Stock Option Award Documents are hereby expressly preserved.

 

(i)             This
Agreement may be executed in one or more counterparts and by facsimile or electronic delivery, each of which shall constitute an original
and all of which together shall constitute one and the same instrument. Signatures of the parties transmitted by facsimile or via .pdf
format shall be deemed to be their original signatures for all purposes. The words “execution,” “signed,” “signature,”
and words of like import shall be deemed to include electronic signatures or the keeping of records in electronic form, each of which
shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping
system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global
and National Commerce Act, the Delaware Uniform Electronic Transactions Act, or any other similar state laws based on the Uniform Electronic
Transactions Act. This Agreement and any signed agreement or instrument entered into in connection with this Agreement, and any amendments
hereto or thereto, to the extent delivered by means of a facsimile machine or electronic mail (any such delivery, an “Electronic
Delivery”), will be treated in all manner and respects as an original agreement or instrument and will be considered to
have the same binding legal effect as if it were the original signed version thereof delivered in person. At the request of any party
hereto or to any such agreement or instrument, each other party hereto or thereto will re-execute original forms thereof and deliver them
to all other parties. No party hereto or to any such agreement or instrument will raise the use of Electronic Delivery to deliver a signature
or the fact that any signature or agreement or instrument was transmitted or communicated through the use of Electronic Delivery as a
defense to the formation of a contract, and each such party forever waives any such defense, except to the extent such defense related
to lack of authenticity.

 

Signatures
on the Following Page

 

    	 	18	 

     

    

 

In
Witness Whereof, the Company and the Executive have executed this Agreement as of the date first above written.

 

	 	 	 
	The Executive:	 	The Company:
	 	 	 
	 	 	 NeuroBo Pharmaceuticals, Inc.
	 	 	 
	 	 	 
	/s/ Gil Price 	 	By:	 /s/ Douglas  Swirsky
	Gil Price	 	Name:	Douglas J. Swirsky
	 	 	Title:	Chairman

 

SIGNATURE
PAGE TO

EMPLOYMENT
AGREEMENT

 

     

     

    

 

Exhibit A

 

FORM OF
RELEASE

 

RELEASE AND WAIVER OF CLAIMS

 

TO BE SIGNED ON OR FOLLOWING THE SEPARATION
DATE ONLY

 

In consideration of the payments
and other benefits set forth in the Employment Agreement effective November___, 2021, to which this form is attached, I, Gil
Price, hereby furnish NeuroBo Pharmaceuticals, Inc., a Delaware corporation
(the “Company”), with the following release and waiver (this “Release and Waiver”).

 

In exchange for the consideration
provided to me by the Employment Agreement that I am not otherwise entitled to receive, I, on behalf of myself and each other Releasing
Party, hereby generally and completely release the Company and its current and former directors, officers, employees, stockholders, partners,
agents, attorneys, predecessors, successors, parent and subsidiary entities, insurers, affiliates, and assigns (collectively, the “Released
Parties”) from any and all claims, liabilities and obligations, both known and unknown, that arise out of or are in any
way related to events, acts, conduct, or omissions occurring prior to or on the date that I sign this Agreement (collectively, the “Released
Claims”). The Released Claims include, but are not limited to: (a) all claims arising out of or in any way related
to my employment with the Company, or the termination of that employment; (b) all claims related to my compensation or benefits from
the Company including salary, bonuses, commissions, vacation pay, expense reimbursements, severance pay, fringe benefits, stock, stock
options, or any other ownership interests in the Company; (c) all claims for breach of contract, wrongful termination, and breach
of the implied covenant of good faith and fair dealing; (d) all tort claims, including claims for fraud, defamation, emotional distress,
and discharge in violation of public policy; and (e) all federal, state, and local statutory claims, including claims for discrimination,
harassment, retaliation, misclassification, attorneys’ fees, or other claims including, but not limited to, claims arising under
the federal Civil Rights Act of 1964 (as amended), the federal Americans with Disabilities Act of 1990, the federal Age Discrimination
in Employment Act of 1967 (as amended) (the “ADEA”), any claim under Title 20 of the State Government Article of
the Maryland Annotated Code, applicable county and local law, and any other law prohibiting employment discrimination, or any claim of
breach of contract (express or implied), wrongful or constructive discharge, or any other tort or statutory claim of whatever kind, Massachusetts
Law Prohibiting Unlawful Discrimination, as amended, Mass. Gen. Laws ch. 151B, § 1 et seq., Massachusetts Discriminatory Wage Rates
Penalized Law (Massachusetts Equal Pay Law), as amended, Mass. Gen. Laws ch. 149, § 105A et seq., Massachusetts Right to be Free
from Sexual Harassment Law, Mass. Gen. Laws ch. 214, § 1C, Massachusetts Discrimination Against Certain Persons on Account of Age
Law, Mass. Gen. Laws ch. 149, § 24A et seq., Massachusetts Equal Rights Law, Mass. Gen. Laws ch. 93, § 102 et seq., Massachusetts
Violation of Constitutional Rights Law, Mass. Gen. Laws ch. 12, § 11I, Massachusetts Family and Medical Leave Law, Mass. Gen. Laws
ch. 149, § 52D; and the Massachusetts Wage Act, Mass. Gen. Laws ch. 149, § 148, et seq.

 

    	 	
Exhibit A-1	 

     

    

 

Notwithstanding the foregoing,
the following are not included in the Released Claims (the “Excluded Claims”): (i) any rights or claims
for indemnification I may have pursuant to the Company’s Third Amended and Restated Certificate of Incorporation, the Company’s
Second Amended and Restated Bylaws, any indemnification agreement entered into between the Company and me or under applicable law; (ii) any
rights or claims to unemployment compensation under applicable law, funds accrued in my 401k account; or (c) any rights that are
not waivable as a matter of law. As used herein, “Releasing Party” means any of me and/or my heirs, successors,
affiliates and/or assigns, and/or any individual or entity who could assert a claim through me or any of them, on my or their behalf,
or as a result of my employment or relationship with or services to the Company or any Released Party, and “Releasing Parties”
means all of them collectively.

 

I acknowledge that, among
other rights, I am waiving and releasing any rights I may have under ADEA, that this Release and Waiver is knowing and voluntary,
and that the consideration given for this Release and Waiver is in addition to anything of value to which I was already entitled as an
executive of the Company. I further acknowledge that I have been advised, as required by the Older Workers Benefit Protection Act, that:
(a) the release and waiver granted herein does not relate to claims under the ADEA which may arise after this Release and Waiver
is executed; (b) I should consult with an attorney prior to executing this Release and Waiver; and (c) if I am age 40 or older
at the time of execution of this release, I have twenty-one (21) days from the date of termination of my employment with the Company
in which to consider this Release and Waiver (although I may choose voluntarily to execute this Release and Waiver earlier); and (d) if
I am age 40 or older at the time of execution of this release, I have seven (7) days following the execution of this Release
and Waiver to revoke my consent to this Release and Waiver and this Release and Waiver shall not be effective until the seven (7) day
revocation period has expired without my having previously revoked this Release and Waiver.

 

I hereby (a) represent
and warrant that neither I nor any other Releasing Party has assigned or transferred any Released Claim and, other than the Excluded Claims, I
am not aware of any claims I or any Releasing Party have or may have against any of the Released Parties that are not included in the
Released Claims; and (b) acknowledge and agree that this Release and Waiver will be effective as a bar to each and every Released
Claim. I agree that I will not receive any monetary damages, recovery and/or relief of any type related to any Claim, whether pursued
by me or any governmental agency, other person or group and that I will opt out of any class or collective action pursued against the
Company or any other Released Party.

 

I agree not to disparage the
Company and its officers, directors, employees, stockholders and/or agents, in any manner likely to be harmful to them or their business,
business reputations or personal reputations; provided that I may respond accurately and fully to any question, inquiry or request for
information when required by legal process (e.g., a valid subpoena or other similar compulsion of law) or as part of a government investigation.

 

I acknowledge my continuing
obligations under certain agreements between me and the Company. Pursuant to certain agreements between me and the Company, I understand
that among other things, I must not use or disclose any confidential or proprietary information of the Company and I must immediately
return all Company property and documents (including all embodiments of proprietary information) and all copies thereof in my possession
or control. I understand and agree that my right to the severance pay I am receiving in exchange for my agreement to the terms of this
Release and Waiver is contingent upon my continued compliance with certain agreements between me and the Company.

 

    	 	
Exhibit A-2	 

     

    

 

I agree to cooperate and to
cause each Releasing Party to cooperate with the Released Parties in any internal investigation, any audit, any administrative, regulatory
or judicial proceeding or any dispute with a third party that may be ongoing or that may arise at any time after the date this Agreement
is signed by me, if and to the extent requested by the Company. My and the Releasing Parties’ cooperation may include being available
to the Company upon reasonable notice for interviews and factual investigations, appearing at the Company’s request to give testimony
without requiring service of a subpoena or other legal process, volunteering to the Company pertinent information and turning over to
the Company all relevant documents which are or may come into my possession.

 

I will not and will cause
each other Releasing Party not to cooperate with, or assist in, any third-party claim, charge, lawsuit, investigation or arbitration against
any Released Party, except to the extent compelled to do so by a lawfully issued subpoena, by court order or by law. If I become aware
that any Releasing Party is served with a subpoena or is compelled by court order or law to testify or produce documents in any type of
proceeding involving any Released Party, except to the extent prohibited by law from doing so, I must immediately advise the Company
of same and cooperate with and cause each other Releasing Party to cooperate with the Company in objecting to such request and/or seeking
confidentiality protections.

 

This Release and Waiver will
be enforceable to the fullest extent permitted by law. If any provision is held to be unenforceable, then such provision will be construed
or revised in a manner so as to permit its enforceability to the fullest extent permitted by applicable law. If such provision cannot
be reformed in that manner, such provision will be deemed to be severed from this Release and Waiver, but every other provision of this
Agreement will remain in full force and effect. This Release and Waiver may not be amended, modified, waived or terminated except in a
writing signed by the Company and you.

 

Except as otherwise provided
herein, this Waiver and Release will be binding upon and inure to the benefit of the parties’ respective successors, permitted
assigns and transferees, personal representatives, heirs and estates, as the case may be; provided, however, that my and
the Releasing Parties’ rights and obligations under this Waiver and Release may not be assigned or delegated without the express
prior written consent of the Company, and any such assignment without the express prior written consent of the Company will be null and
void ab initio. I further acknowledge and agree that all of the Released Parties are intended third-party beneficiaries
of and will be entitled to rely on and enforce my obligations under this Release and Waiver.

 

This Release and Waiver constitutes
the complete, final and exclusive embodiment of the entire agreement between the Company and me with regard to the subject matter hereof.
I am not relying on any promise or representation by the Company that is not expressly stated herein.

 

	Date:	 	 	By:	 
	 	 	 	Gil Price

 

    	 	
Exhibit A-3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00335-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00335-of-00352.parquet"}]]